World Health Organization Raises Alert Over Acute Scarcity of Weight-Loss Medications
Fewer than one in 10 patients that would benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it publishes its first advice on the medications.
Considering more than one billion individuals worldwide currently living with obesity, it is calling for increased and just availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The new guidelines recognises that excess weight is a chronic disease that can be addressed with comprehensive and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are major barriers to universal availability to the jabs that can help people shift significant weight, says the organization.
Weight-Loss Drug Shortage
Even in the present best projected case, the production of such drugs would only suffice for approximately 100 million people – less than 10% of the global need, as stated by the health organization.
The guideline encourages nations and manufacturers to widen access, via strategies like voluntary licensing.
A patent on semaglutide – the main component of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Jabs Work
These medications mimick a biological compound to delay gastric emptying, curb appetite and boost the sense of being full so users reduce food intake.
Patients commonly start to lose weight after several weeks of commencing the once-weekly jabs.
Studies points to patients may put most of the weight back on a year later of stopping the medication, because their typical appetite resume.
To be above a healthy weight elevates your likelihood for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts people in every country and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.
